Postmedia Calgary receives three honours at National Newspaper Awards
Postmedia Calgary — the Calgary Herald and Calgary Sun — received three honours at the National Newspaper Awards (NNA) on Friday night. The news organization was given a finalist award in three categories:
Article content
Article content
Photojournalist Jim Wells was a finalist in the News Photo category for an unforgettable image of two neighbours trying to save a deer that fell through the ice of the Bow River in the Inglewood area last November.
A regular contributor to the paper's Opinion pages, Patrick LaMontagne was a finalist in the category of Editorial Cartooning for his captivating artwork and sharp commentary.
A months-long project called Squeezed: Navigating Calgary's high cost of living was also given a finalist award in the Project of the Year category.
Article content
Article content
'It's remarkable to have three NNA finalist honours in one year,' said Postmedia Calgary editor Monica Zurowski. 'We are grateful for this recognition and even more grateful that thousands and thousands of readers allow us the privilege of bringing them local news and local content that matters.
Article content
Article content
'The journalism honoured by these awards represents a small cross-section of the news, business, arts, sports, opinion, photography and video content that we create every day,' Zurowski said. 'We're committed to bringing compelling and meaningful content to our community in all these areas every day.'
Article content
Including the three honours received by its Calgary newsroom, Postmedia received a total nine honours this year for work by journalists from The Financial Post, Vancouver Sun/The Province, Ottawa Citizen/Sun, Halifax Chronicle Herald, Saskatoon StarPhoenix and Regina Leader-Post. The honours included a first-place award for Brandon Harder of the Regina Leader-Post for his painstaking re-creation of what happened when police went undercover to wring out a confession from a cold-case murderer.
Article content
Held in Montreal, this year's NNAs represented the 76th year of the awards program. There were 69 finalists in 23 categories, representing 26 news organizations, out of a total 864 entries submitted by 82 news organizations. The awards were established in 1949 to encourage excellence and reward achievement in daily newspaper work in Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
02-06-2025
- Winnipeg Free Press
Britain is getting a defense boost aimed at sending a message to Moscow, and to Trump
LONDON (AP) — The United Kingdom will build new nuclear-powered attack submarines and create an army ready to fight a war in Europe as part of a boost to military spending designed to send a message to Moscow — and Washington. Prime Minister Keir Starmer said Britain 'cannot ignore the threat that Russia poses' as he pledged to undertake the most sweeping changes to Britain's defenses since the end of the Cold War more than three decades ago. 'We have to recognize the world has changed,' Starmer told the BBC. 'With greater instability than there has been for many, many years, and greater threats.' What's happening on Monday? The government is to respond to a strategic defense review commissioned by Starmer and led by George Robertson, a former U.K. defense secretary and NATO secretary general. It's the first such review since 2021, and lands in a world transformed by Russia's full-scale invasion of Ukraine in 2022, and by the re-election of President Donald Trump last year. The government says it will accept all 62 recommendations made in the review, aiming to help the U.K. confront growing threats on land, air sea and in cyberspace. Defense Secretary John Healey said the changes would send 'a message to Moscow, and transform the country's military following decades of retrenchment, though he said he does not expect the number of soldiers — currently at a historic low — to rise until the early 2030s. Healey said plans for defense spending to hit 2.5% of national income by 2027 a year are 'on track' and that there's 'no doubt' it will hit 3% before 2034. Starmer said the 3% goal is an 'ambition,' rather than a firm promise, and it's unclear where the cash-strapped Treasury will find the money. The government has already, contentiously, cut international aid spending to reach the 2.5% target. Starmer said he wouldn't make a firm pledge until he knew 'precisely where the money is coming from.' Deterring Russia Even 3% falls short of what some leaders in NATO think is needed to deter Russia from future attacks on its neighbors. NATO chief Mark Rutte says leaders of the 32 member countries will debate a commitment to spend at least 3.5% of GDP on defense when they meet in the Netherlads this month. Monday's announcements include building 'up to 12' nuclear-powered, conventionally armed submarines under the AUKUS partnership with Australia and the United States. The government also says it will invest 15 billion in Britain's nuclear arsenal, which consists of missiles carried on a handful of submarines. Details of those plans are likely to be scarce. The government will also increase conventional Britain's weapons stockpiles with up to 7,000 U.K.-built long-range weapons. Starmer said rearming would create a 'defense dividend' of well-paid jobs — a contrast to the post-Cold War 'peace dividend' that saw Western nations channel money away from defense into other areas. Like other NATO members, the U.K. has been reassessing its defense spending since Russia's full-scale invasion of Ukraine in February 2022. Healey said Russia is 'attacking the U.K. daily,' with 90,000 cyberattacks from state-linked sources directed at the U.K.'s defense over the last two years. A cyber command to counter such threats is expected to be set up as part of the review. 'This is a message to Moscow,' Healey told the BBC. Monday Mornings The latest local business news and a lookahead to the coming week. Bolstering Europe's defenses It's also a message to Trump that Europe is heeding his demand for NATO members to spend more on their own defense. European countries, led by the U.K. and France, have scrambled to coordinate their defense posture as Trump transforms American foreign policy, seemingly sidelining Europe as he looks to end the war in Ukraine. Trump has long questioned the value of NATO and complained that the U.S. provides security to European countries that don't pull their weight. Robert Jenrick, justice spokesman for the main opposition Conservative Party, called on the government to be more ambitious and raise spending to 3% of national income by 2029. 'We think that 2034 is a long time to wait, given the gravity of the situation,' he told Sky News.
Calgary Herald
01-06-2025
- Calgary Herald
Calgary police investigating suspicious death in Auburn Bay
A Calgary Police Service SUV is shown outside headquarters in northeast Calgary on Feb. 27, 2025. Jim Wells/Postmedia The Calgary Police Service's homicide unit is investigating what they call a suspicious death in the southeast community of Auburn Bay. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Calgary Herald ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Calgary Herald ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Police were called to the 1000 block of Auburn Bay Circle S.E. shortly before 3 p.m. Saturday for reports of a man who was believed to be dead inside a residence. A deceased man was found inside the home, and as of Sunday, police are continuing to investigate the death. 'There is currently no risk to the public,' police said in an earlier statement. An autopsy on the deceased man is to be conducted by the Office of the Chief Medical Examiner on Monday. Police said no further information would be provided until the autopsy was complete.
Cision Canada
30-05-2025
- Cision Canada
BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
VANCOUVER, BC, May 30, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces a proposed consolidation of the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and a concurrent brokered private placement offering (the " Offering") consisting of a minimum of 5,714,285 units of the Company (each, a " Unit") at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Consolidation The Company currently has 293,425,203 Common Shares issued and outstanding, and it is anticipated that immediately following the Consolidation, excluding Common Shares to be issued in connection with this Offering, the Company will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. The exercise or conversion price of the Company's convertible securities and the number of Common Shares issuable thereunder will also be proportionately adjusted upon completion of the Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the proposed Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common Share or greater, or rounded down in the case of a fractional interest that is less than one-half (1/2) of a Common Share, to the nearest whole number of Common Shares, and no cash consideration will be paid in respect of fractional Common Shares rounded down to the nearest whole Common Share. The Company will issue a subsequent news release in respect of the proposed Consolidation to announce the effective date of the Consolidation, the new CUSIP and ISIN for the post-Consolidation Common Shares, and any other relevant details, and file all necessary documentation with the Canadian Securities Exchange (the " CSE") in respect of the proposed Consolidation. The post-Consolidation Common Shares will continue to trade on the CSE under the Company's existing name and trading symbol. The Consolidation remains subject to requisite approvals, including acceptance by the CSE. Offering The Company has entered into an agreement with D12 Capital Markets Inc. (" D12") and its affiliate, Foundation Markets Inc. to act as agents (the " Agents") in connection with the Offering. Completion of the Offering will be contingent upon the Company issuing a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.60 for a period of 36 months from the closing date of the Offering. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Upon successful closing of the Offering, the Agents will receive a cash commission equal to 8% of the gross proceeds committed to the Company from any party introduced by the Agents. Such payment shall be paid by the Company in equal share to the Agents as per their direction. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company and the Agents may agree upon provided such date is on or before July 14, 2025. Closing of the Offering and payment of the Agents' commission are subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an offering document dated May 30, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
